ClinicalTrials.gg
CompletedNCT07432815Updated Oct 5, 2026

Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined Methotrexate and Antidepressant

A Phase 4 interventional study of Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety and Methotrexate in Depression, Anxiety and Psoriasis, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Cairo University · Phase 4, Interventional, and Treatment

How we know

Updated Oct 5, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Depression by Cairo University — 7 open to participants now, 7 under way, none of them phase 3. Depression · Cairo University.

Enrollment
11th of 17
40 · median 50
Started
2026
with 4 others
Phase 4
Only one
of the 20
Registered
16th of 20
by date

Among the 20 studies in Depression by Cairo University, this one is the 11th largest by enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 4, and was the 16th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

7 of the 20 studies in Depression by Cairo University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Depression by Cairo University, or all of them as a file.
02

Study summary

This randomized controlled trial aims to compare the efficacy of methotrexate (MTX) monotherapy versus combined methotrexate and selective serotonin reuptake inhibitor (SSRI) therapy in patients with psoriasis and comorbid depression and/or anxiety. Participants will be randomly assigned to two groups: one receiving MTX alone and the other receiving MTX plus escitalopram. Clinical outcomes will be evaluated over a 6-month period, including psoriasis severity using the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA), quality of life using the Dermatology Life Quality Index (DLQI), and psychological status using the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Hamilton Depression Rating Scale (HAM-D), and Hamilton Anxiety Rating Scale (HAM-A). The study will assess whether combination therapy provides superior clinical and psychological outcomes.

03

Conditions studied

  • Depression
  • Anxiety
  • Psoriasis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged >18 and \<60 years
  • Moderate to severe psoriasis (PASI ≥10 or BSA ≥10%)
  • Moderate to severe depression (BDI ≥20 or HAM-D ≥17) and/or moderate to severe anxiety (BAI ≥16 or HAM-A ≥25)

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse
  • Systemic psoriasis treatment within the past 3 months
  • Pregnancy or breastfeeding
  • to methotrexate or escitalopram
  • Erythrodermic or pustular psoriasis
  • to methotrexate (e.g., hepatic disease or )
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Active comparator
    Methotrxate only

    Methotrexate 0.4mg/kg for 6 months in psoriasis patients

    Drug: Methotrexate

  • Experimental
    Methotrexate and SSRI

    Methotrexate 0.4mg/kg and escitalopram 10mg for 6 months in psoriasis patients

    Combination Product: Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety

Interventions

  • Combination productCombination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety

    Combination of methotrexate and escitalopram in treatment of psoriasis patients with depression and/or anxiety

  • Methotrexate 0.4mg/kg once weekly for 6 months

06

What researchers measure

Primary outcomes

  1. comparison of Percentage change in PASI score from baseline to 6 months between group A and B

    Time frame: 6 months

  2. Comparison between percentage change of BDI, BAI, Ham-A and Ham-D in groups A&B

    Time frame: 6 months

  3. Comparison of percentage of patients who achieved PASI 75%, 90% & 100% between groups A & B

    Time frame: 6 months

07

Study locations

1 site
  • Kasralainy
    Cairo, Cairo Governorate 11562, Egypt
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Jun 2026, 4 months.

Of 110 non-industry phase 4 interventional studies under Depression, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 59. This study's 4 months is below that.

Counting every sponsor, half of 119 studies reached it within 32 months; a quarter within 17 and three quarters within 59.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Dec 2026 → Jun 2026 and completion Dec 2026 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2026
First posted
Feb 25, 2026
StartActual
Feb 1, 2026
Primary completionActual
Jun 1, 2026was Dec 2026
CompletionActual
Jun 14, 2026was Dec 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 5, 2026
Primary completion
Dec 1, 2026→Jun 1, 2026 (actual)
Oct 5, 2026
Study completion
Dec 30, 2026→Jun 14, 2026 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Completed
    Primary completion Dec 1, 2026→Jun 1, 2026 (now actual)
    Study completion Dec 30, 2026→Jun 14, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07432815
Lead sponsor
Cairo University
Responsible party
Naglaa Mohsen Hussien (Resident, Cairo University) — Principal investigator
First posted
Feb 25, 2026
Start date
Feb 1, 2026
Primary completion
Jun 1, 2026
Completion
Jun 14, 2026
Last update
Oct 5, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion